An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. (2020)
Attributed to:
Physical Activity Epidemiology
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00125-019-05062-x
PubMed Identifier: 31858186
Publication URI: http://europepmc.org/abstract/MED/31858186
Type: Journal Article/Review
Volume: 63
Parent Publication: Diabetologia
Issue: 4
ISSN: 0012-186X